ERLOTINIB: EFFICACY IN NON-SMALL CELL LUNG CANCER (2nd AND SUBSEQUENT LINES OF THERAPY)

作者：Sendra Juan Moll; Mari Asuncion Albert; Company Enrique Soler

来源：Atencion Farmaceutica, 2013, 15(4): 230-+.

Objective: To assess the progression-free survival in non-small cell lung cancer in patients treated with erlotinib, with second or subsequent lines of therapy at a tertiary general hospital, and compare the subgroups analysis with previous studies. %26lt;br%26gt;Method: An observational, retrospective study (48.5 months) in 21 patients. The main variable was the progression-free survival in months; second variables were overall survival, toxicity and disease control rate. %26lt;br%26gt;Results: The median of progression-free survival was 2.7 months (1.77-3.64, CI 95%). The log-rank test showed greater progression-free survival if EGFR mutations existed (p = 0.006), non-smokers (p = 0.019) and females (p = 0.049). %26lt;br%26gt;Conclusion: The results were consistent with most of previous studies conducted on other groups of patients.

• 出版日期2013-8